An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 10, 2021 indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 6,500,000 shares i.e. 28.77% of Celyad Oncology’s shares and 26.04% voting rights as of 8 December 2021.
Content of the Notification:
Reason of the Notification:
Upward crossing of the 25% threshold
Acquisition of voting securities or voting rights
Notification by:
A parent undertaking or a controlling person
Persons subject to the notification requirement:
Fortress Investment Group LLC. – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA
CFIP CLYD LLC – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA
Transaction date
December 8, 2021
Threshold that is crossed (in %)
25
Denominator
22,593,956
Notified details:
A) Voting Rights
Previous notification
After the Transaction
#of voting rights
# of voting rights
% of voting rights
Holders of voting rights
Linked to the securities
Not linked to the securities
Linked to the securities
Not linked to the securities
Fortress Investment Group LLC
0
0.00%
CFIP CLYD LLC
6,500,000
26.04%
Subtotal
6,500,000
26.04%
TOTAL
6,500,000
26.04%
Chain of controlled undertakings through which the holdings is effectively held
Fortress Investment Group LLC indirectly controls 100% of the members of CFIP CLYD LLC, which are various Fortress Funds. Fortress Investment Group LLC has no controlling shareholder.
Miscellaneous
The Press Release may be consulted on the website of Celyad Oncology via this link.
The notification can be consulted on the website if Celyad Oncology via this link.
Contact person(s):
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Forward-looking statements
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).